Spots Global Cancer Trial Database for carcinoma, renal cell
Every month we try and update this database with for carcinoma, renal cell cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer | NCT00282048 | Kidney Neoplasm... Carcinoma, Rena... | AG-013736 (axit... | 18 Years - | Pfizer | |
| A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer | NCT01021059 | Melanoma Carcinoma, Rena... | rh IL-15 | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors | NCT04572451 | Melanoma Carcinoma, Rena... Unresectable So... | nivolumab BMS-986253 Stereotactic Bo... | 18 Years - | University of Pittsburgh | |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® | NCT00771147 | Carcinoma, Rena... Carcinoma, Rena... | Sorafenib (Nexa... | 18 Years - | Bayer | |
| A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma | NCT04028245 | Carcinoma, Rena... | Spartalizumab Canakinumab | 18 Years - 99 Years | Columbia University | |
| A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | NCT00523640 | Carcinoma, Rena... | combination of ... | 18 Years - | University of Chicago | |
| RGD-PET-CT in Cancer Angiogenesis | NCT01492192 | Carcinoma, Rena... | 18F-RGD-PET-CT ... | 18 Years - | Oxford University Hospitals NHS Trust | |
| Mobile Intervention - Physical Activity in Cancer Treatment | NCT03671304 | Carcinoma, Rena... | Fitbit Versa | 18 Years - 89 Years | University of Texas Southwestern Medical Center | |
| VEG111485: A QTc Study of Pazopanib | NCT00861029 | Carcinoma, Rena... | Pazopanib Placebo for paz... Moxifloxacin Placebo for mox... | 18 Years - | GlaxoSmithKline | |
| Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer | NCT00440973 | Carcinoma, Rena... | Bevacizumab Interleukin-2 | 18 Years - | The Methodist Hospital Research Institute | |
| SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma | NCT00089648 | Carcinoma, Rena... | Sunitinib | 18 Years - | Pfizer | |
| PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) | NCT00043368 | Melanoma Breast Neoplasm... Carcinoma, Rena... Lymphoma, T-Cel... Carcinoma, Non-... | PF-3512676 | 18 Years - | Pfizer | |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | NCT02386111 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Hi... Clear-cell Meta... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer | NCT01189370 | Renal Cell Canc... | sorafenib | 18 Years - | University of Kansas Medical Center | |
| VEG111485: A QTc Study of Pazopanib | NCT00861029 | Carcinoma, Rena... | Pazopanib Placebo for paz... Moxifloxacin Placebo for mox... | 18 Years - | GlaxoSmithKline | |
| A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma | NCT04028245 | Carcinoma, Rena... | Spartalizumab Canakinumab | 18 Years - 99 Years | Columbia University | |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | NCT02962804 | Carcinoma, Rena... | Nivolumab Radiation | 18 Years - | University of Kansas Medical Center | |
| Prognostic Factor for Renal Cell Carcinoma (RCC) With Venous Tumor Thrombus | NCT01328691 | Carcinoma, Rena... Thrombus | 18 Years - | Seoul National University Hospital | ||
| GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma | NCT00244764 | Carcinoma, Rena... | GW786034 Placebo | 21 Years - | GlaxoSmithKline | |
| Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma | NCT00044564 | Carcinoma, Rena... | Bay 59-8862 | 18 Years - | Bayer | |
| A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | NCT00523640 | Carcinoma, Rena... | combination of ... | 18 Years - | University of Chicago | |
| A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment | NCT04338269 | Carcinoma, Rena... | Atezolizumab Cabozantinib | 18 Years - | Hoffmann-La Roche | |
| Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting | NCT01557127 | Carcinoma, Rena... | Sorafenib (Nexa... | 18 Years - | Bayer | |
| Regulatory Post Marketing Surveillance Study on Nexavar® | NCT01012011 | Carcinoma, Hepa... Carcinoma, Rena... | Sorafenib (Nexa... | 20 Years - 91 Years | Bayer | |
| An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION) | NCT04941768 | Carcinoma, Rena... | 18 Years - | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | ||
| Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer | NCT00440973 | Carcinoma, Rena... | Bevacizumab Interleukin-2 | 18 Years - | The Methodist Hospital Research Institute | |
| Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients | NCT02324803 | Self Efficacy Adverse Drug Ev... Carcinoma, Rena... | pazopanib | 18 Years - | Southern China Urology Cancer Consortium | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| KIDSTAGE- Staging of Kidney Cancer Using Dual Time PET/CT and Other Biomarkers | NCT04295174 | Carcinoma, Rena... | 18 Years - | Odense University Hospital | ||
| Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses | NCT02248389 | Carcinoma, Rena... | Sonatherm 600i ... | 18 Years - 80 Years | Indiana University | |
| Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing | NCT03109015 | Carcinoma, Rena... | Sunitinib Sunitinib | 18 Years - | Duke University | |
| A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) | NCT02627963 | Carcinoma, Rena... | Tivozanib hydro... Sorafenib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma | NCT00095186 | Carcinoma, Rena... | Recombinant Hum... | 18 Years - | Agennix | |
| A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma | NCT01677390 | Renal Cell Carc... | SGN-75 everolimus | 18 Years - | Seagen Inc. | |
| Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) | NCT02454478 | Carcinoma, Rena... | Lenvatinib Everolimus | 20 Years - | Eisai Inc. | |
| Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy | NCT01195649 | Carcinoma, Rena... | Sorafenib (Nexa... | 18 Years - | Bayer | |
| Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion | NCT05589207 | Carcinoma, Rena... Tumor Thrombus Neoplasm Invasi... Inferior Vena C... | Vascular wall i... | 18 Years - | Peking University Third Hospital | |
| RGD-PET-CT in Cancer Angiogenesis | NCT01492192 | Carcinoma, Rena... | 18F-RGD-PET-CT ... | 18 Years - | Oxford University Hospitals NHS Trust | |
| Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging | NCT00842790 | Carcinoma, Rena... | 18 Years - 85 Years | Assistance Publique - Hôpitaux de Paris | ||
| Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma | NCT02782715 | Carcinoma, Rena... | Stereotactic Bo... Microwave Ablat... | 18 Years - | University of Wisconsin, Madison | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma | NCT01147822 | Carcinoma, Rena... | Pazopanib Sunitinib | 18 Years - | Novartis | |
| Savolitinib vs. Sunitinib in MET-driven PRCC. | NCT03091192 | Carcinoma Carcinoma, Rena... Kidney Neoplasm... Urologic Neopla... Kidney Diseases Neoplasms by Si... Enzyme Inhibito... Protein Kinase ... | Savolitinib Sunitinib | 18 Years - 130 Years | AstraZeneca | |
| Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma | NCT00111020 | Carcinoma, Rena... | Sorafenib (Nexa... | 15 Years - | Bayer | |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | NCT02962804 | Carcinoma, Rena... | Nivolumab Radiation | 18 Years - | University of Kansas Medical Center | |
| Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | NCT00522249 | Carcinoma, Rena... | Pegylated Alfa ... sunitinib erlotinib | 18 Years - | The Methodist Hospital Research Institute | |
| A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | NCT04195750 | Carcinoma, Rena... | Belzutifan Everolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. | NCT00077974 | Carcinoma, Rena... | SU011248 | 18 Years - | Pfizer | |
| Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma | NCT05287945 | Carcinoma, Rena... | Orellanine | 18 Years - | Oncorena AB | |
| Prognostic Significance of Preoperative Hemoglobin A1c (HbA1c) in Renal Cell Carcinoma | NCT02417194 | Carcinoma, Rena... Pathology Treatment Outco... Hemoglobin A1c ... | 20 Years - 80 Years | Seoul National University Hospital | ||
| Detection of Renal Malignancy of Complicated Renal Cysts | NCT01087060 | Kidney Neoplasm Cysts Carcinoma, Rena... | partial or radi... | 20 Years - 80 Years | Seoul National University Hospital | |
| Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer | NCT00446368 | Carcinoma, Rena... | RAD001 | 18 Years - | The Methodist Hospital Research Institute | |
| Safety and Efficacy of Sutureless Zero Ischemia Laparoscopic Tumor Enucleation for T1 Stage Renal Carcinoma | NCT05790122 | Carcinoma, Rena... Kidney Neoplasm... | 18 Years - 80 Years | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | ||
| Glycosaminoglycan Scores as Monitoring Biomarkers in Confined Renal Cell Carcinoma | NCT02732652 | Carcinoma, Rena... | 18 Years - | Chalmers University of Technology | ||
| Effect on Pre-operative Anxiety of a Personalized Three-dimensional Kidney Model Prior to Nephron-sparing Surgery for Renal Tumor. | NCT03943771 | Kidney Neoplasm... Carcinoma, Rena... | Anxiety, renal ... | 18 Years - | University Hospital, Bordeaux | |
| Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan) | NCT00716625 | Carcinoma, Rena... | sunitinib malat... | 0 Days - | Pfizer | |
| A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | NCT04544748 | Carcinoma, Non-... Carcinoma, Rena... Melanoma | GNR-051 | 18 Years - | AO GENERIUM | |
| Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma | NCT00130897 | Carcinoma, Rena... | Sutent | 18 Years - | Pfizer | |
| An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma | NCT00992121 | Carcinoma, Rena... | Bevacizumab Pazopanib 2 wee... Pazopanib 3 wee... | 18 Years - | GlaxoSmithKline | |
| Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging | NCT00842790 | Carcinoma, Rena... | 18 Years - 85 Years | Assistance Publique - Hôpitaux de Paris | ||
| A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. | NCT01441388 | Carcinoma, Rena... Glioblastoma Carcinoma, Hepa... | Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... | 18 Years - | Pfizer | |
| Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma | NCT02729194 | Carcinoma, Rena... | Pazopanib Low Fat Diet | 18 Years - | University of Michigan Rogel Cancer Center | |
| Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer | NCT03111901 | Carcinoma, Rena... Melanoma | Pembrolizumab Interleukin-2 | 18 Years - | University of Virginia | |
| Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma | NCT00056173 | Carcinoma, Rena... Metastases, Neo... | GTI-2040 | 18 Years - | Aptose Biosciences Inc. | |
| Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer | NCT00445523 | Carcinoma, Rena... | TroVax® (Immuno... Interferon-alph... | 18 Years - | The Methodist Hospital Research Institute | |
| A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | NCT04544748 | Carcinoma, Non-... Carcinoma, Rena... Melanoma | GNR-051 | 18 Years - | AO GENERIUM | |
| Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer | NCT00079612 | Carcinoma, Rena... | Sorafenib (Nexa... Placebo | 18 Years - | Bayer | |
| Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma | NCT00044564 | Carcinoma, Rena... | Bay 59-8862 | 18 Years - | Bayer | |
| A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | NCT02952989 | Carcinoma, Non-... Carcinoma, Rena... Breast Neoplasm... Urinary Bladder... Carcinoma, Squa... Colorectal Neop... Gastric Adenoca... Gastroesophagea... | SGN-2FF pembrolizumab | 18 Years - | Seagen Inc. | |
| A Research Study for Patients With Metastatic Renal Cell Carcinoma | NCT00106613 | Carcinoma, Rena... Neoplasm Metast... | FK228 (romideps... | 18 Years - | Celgene | |
| A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer | NCT01021059 | Melanoma Carcinoma, Rena... | rh IL-15 | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Oncobax®-AK in Patients With Advanced Solid Tumors | NCT05865730 | Carcinoma, Rena... Carcinoma, Non-... | Live Bacterial ... | 18 Years - | EverImmune | |
| Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer | NCT05297734 | End of Life Cancer | Receive technol... Receive redesig... | 21 Years - | Stanford University | |
| Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. | NCT01024920 | Carcinoma, Rena... | BIBF 1120 sunitinib | 18 Years - | Boehringer Ingelheim | |
| Study Evaluating Renal Cell Carcinoma Risk Factors | NCT00927043 | Carcinoma, Rena... | Epidemiological... | 18 Years - | Pfizer | |
| Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma | NCT00353301 | Renal Cell Carc... | Erlotinib hydro... Sirolimus | 18 Years - | University of Colorado, Denver | |
| Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018) | NCT02014636 | Carcinoma, Rena... | Pazopanib MK-3475 | 18 Years - | Novartis | |
| Sorafenib Dose Escalation in Renal Cell Carcinoma | NCT00618982 | Carcinoma, Rena... | Sorafenib (Nexa... | 18 Years - | Bayer | |
| Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer | NCT00448149 | Carcinoma, Rena... | RAD001 Sorafenib | 18 Years - | The Methodist Hospital Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
